Indications
Therapeutic Asset Ratings
91,565
assets
·
7,904
sponsors
·
3,128
indications
Methodology v0.2
Filters
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Nivolumab
Refractory Malignant Neoplasm
CatalYm GmbH
P2
BB
(69)
Nivolumab
Triple-Negative Breast Carcinoma
Yale University
P2
BB
(69)
Olaparib
BRCA1-Related Cancer Predisposition
M.D. Anderson Cancer Center
P2
BB
(69)
Pembrolizumab
Metastatic Malignant Neoplasm In The Brain
City of Hope Medical Center
P2
BB
(69)
Pembrolizumab
Castration-Resistant Prostate Carcinoma
Cellbion Co., Ltd.
P2
BB
(69)
Pembrolizumab
Colon Carcinoma
Ismail Gögenur
P2
BB
(69)
Pembrolizumab
Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Seda S. Tolu
P2
BB
(69)
Pembrolizumab
Ovarian Serous Adenocarcinoma
Roswell Park Cancer Institute
P2
BB
(69)
Pembrolizumab
Prostate Adenocarcinoma
OHSU Knight Cancer Institute
P2
BB
(69)
Pembrolizumab
Richter Transformation
Roswell Park Cancer Institute
P2
BB
(69)
Pembrolizumab
Thyroid Cancer
Kineta Inc.
P2
BB
(69)
Peripheral Blood Stem Cells, Allogeneic, Cd34 Positive
Myeloproliferative Neoplasm
Fred Hutchinson Cancer Center
P2
BB
(69)
Polo-Like Kinase 1 Inhibitor Nms-1286937
Colorectal Cancer
Cardiff Oncology
P2
BB
(69)
Ropanicant
Major Depressive Disorder
Suven Life Sciences Limited
P2
BB
(69)
Sirolimus
Adult Acute Lymphoblastic Leukemia
Roswell Park Cancer Institute
P2
BB
(69)
Sirolimus
Burkitt Lymphoma
Masonic Cancer Center, University of Minnesota
P2
BB
(69)
Sirolimus
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer Institute
P2
BB
(69)
Sitagliptin
Acute Myeloid Leukemia
Indiana University
P2
BB
(69)
Sitagliptin
Myelodysplastic Syndrome
Indiana University
P2
BB
(69)
Tafasitamab
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center
P2
BB
(69)
TIL
Metastatic Melanoma
East Metropolitan Health Service, Australia
P2
BB
(69)
Tipiracil
Colorectal Adenocarcinoma
Academic and Community Cancer Research United
P2
BB
(69)
Tipiracil
Rectal Cancer
Academic and Community Cancer Research United
P2
BB
(69)
Tisotumab Vedotin
Head And Neck Squamous Cell Carcinoma
Seagen, a wholly owned subsidiary of Pfizer
P2
BB
(69)
Trifluridine
Rectal Cancer
Academic and Community Cancer Research United
P2
BB
(69)
Showing 3226 to 3250 of 42,285 assets
Previous
Page 130 of 1692
Next